Further to our original Early Notification and Brand Change dated 31 January 2019, we wish to provide this update which has been notified by PHARMAC via the Pharmaceutical Schedule Update for June 2019.

As advised via PHARMAC proposal of 10 December 2018 and the notification of PHARMAC decision of 31 January 2019 there is to be a change in the listing and future sole supply of Atomoxetine.

New listing from 1 November 2019 (previously July 2019)

Atomoxetine Cap 10 mg 28                                Pharmacode TBA                Schedule price $18.41

Atomoxetine Cap 18 mg 28                                Pharmacode TBA                 Schedule price $27.06

Atomoxetine Cap 28 mg 28                                Pharmacode TBA                  Schedule price $29.22

Atomoxetine Cap 40 mg 28                                Pharmacode TBA                 Schedule price $29.22

Atomoxetine Cap 60 mg 28                                Pharmacode TBA                Schedule price $46.51

Atomoxetine Cap 80 mg 28                                Pharmacode TBA                  Schedule price $56.45

Atomoxetine Cap 100 mg 28                              Pharmacode TBA                Schedule price $58.48

 

 

Incumbent brand

Strattera Cap 10 mg 28                                        Pharmacode 2181568          Schedule price $107.03

Strattera Cap 18 mg 28                                        Pharmacode 2181576          Schedule price $107.03

Strattera Cap 25mg 28                                         Pharmacode 2181584          Schedule price $107.03

Strattera Cap 40 mg 28                                        Pharmacode 2181592          Schedule price $107.03

Strattera Cap 60 mg 28                                        Pharmacode 2181541          Schedule price $107.03

Strattera Cap 80 mg 28                                        Pharmacode 2319551          Schedule price $139.11

Strattera Cap 100 mg 28                                     Pharmacode 2319578        Schedule price $139.11

Reference pricing will apply from 1 January 202 (previously 1 September 2019).

HSS (Hospital Supply Status) commences 1 January 2020 (previously 1 September 2019)

CSS (Community Supply Status) commences 1 April 2020 (previously 1 December 2019)

Brand switch fee to apply from 1 April 2020 to 30 June 2020.

As of the date of this notification ProPharma / PWR cannot accept Strattera Capsule for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted. But be very wary of holding stock.

Benefit of staying with incumbent until 1 April 2020

10 mg : – Dispensing is 28 capsules. Therefore 1 x 28 @ $107.03 x 3% = $3.2109 plus $0.253 (pack fee) giving you $3.4639

Compared to $18.41 x 3% = $0.5523 plus $0.253 (pack fee) giving you $0.8053

18 mg : – Dispensing is 28 capsules. Therefore 1 x 28 @ $107.03 x 3% = $3.2109 plus $0.253 (pack fee) giving you $3.4639

Compared to $27.06 x 3% = $0.8118 plus $0.253 (pack fee) giving you $1.0648

25 mg : – Dispensing is 28 capsules. Therefore 1 x 28 @ $107.03 x 3% = $3.2109 plus $0.253 (pack fee) giving you $3.4639

Compared to $29.22 x 3% = $0.8766 plus $0.253 (pack fee) giving you $1.1296

40 mg : – Dispensing is 28 capsules. Therefore 1 x 28 @ $107.03 x 3% = $3.2109 plus $0.253 (pack fee) giving you $3.4639

Compared to $29.22 x 3% = $0.8766 plus $0.253 (pack fee) giving you $1.1296

60 mg : – Dispensing is 28 capsules. Therefore 1 x 28 @ $107.03 x 3% = $3.2109 plus $0.253 (pack fee) giving you $3.4639

Compared to $46.51 x 3% = $1.3953 plus $0.253 (pack fee) giving you $1.6483

80 mg : – Dispensing is 28 capsules. Therefore 1 x 28 @ $139.11 x 3% = $4.1733 plus $0.253 (pack fee) giving you $4.4263

Compared to $56.45 x 3% = $1.6935 plus $0.253 (pack fee) giving you $1.9465

100 mg : – Dispensing is 28 capsules. Therefore 1 x 28 @ $139.11 x 3% = $4.1733 plus $0.253 (pack fee) giving you $4.4263

Compared to $58.48 x 3% = $1.7544 plus $0.253 (pack fee) giving you $2.0074

You MUST manage your stock so that you have ZERO stock at time of reference pricing 1 January 2020. Failure to do so could prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close